Industry news round-up: the latest oncology updates from May

Written by Rachel Jenkins, Future Science Group

Take a look at the industry headlines from the last month, including the latest FDA approvals, European licencing and an investigation into the financial relationships between industry and leaders of influential medical associations. European Commission grants marketing authorization for encorafenib–cetuximab combination Pierre Fabre (Paris, France) have announced that they have received European Commission Marketing Authorization for the combination of encorafenib plus cetuximab for the treatment of adult patients with BRAFv600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy. The license is based on the Phase III BEACON CRC trial, which found that the combination demonstrated a significant improvement...

To view this content, please register now for access

It's completely free